



Adherium Appoints New CFO

San Mateo, CA - September 19, 2017: Adherium (ASX: ADR), a digital health company that improves medication adherence and patient outcomes, today announced the appointment of Timothy A. Marcotte as its new Chief Financial Officer. Mr. Marcotte will join the Company's leadership team and be based out of the Company's U.S. headquarters in San Mateo, California.

Arik Anderson, CEO of Adherium, said: "We are thrilled to have Tim join the Adherium team. His extensive experience in overseeing product rollouts into new markets will be invaluable and contribute significantly to our future strategy in the United States. We continue to build out our presence in the US, and a recent 510(k) clearance and new product releases signify our growing commercial activities in the region."

Timothy A. Marcotte, Chief Financial Officer

Mr. Marcotte has more than 35 years of experience working at public and private medical device companies holding various C-level positions, including CEO, CFO and COO. Prior to joining Adherium, he worked at several medical device companies, including Zonare Medical Systems, VNUS Medical Technologies, and Repeater Technologies. Mr. Marcotte's experience includes overseeing multiple initial public offerings through his prior CFO roles. He earned an MBA from the University of Michigan.

Former CFO Rob Turnbull transitions to a new role of Vice President of Finance and Business Services. In this role Mr. Turnbull will assume a number of additional operational responsibilities across Adherium.

Adherium recently hit a number of new commercial milestones with the 100,000th Smartinhaler sold, FDA clearance of its next generation Smartinhaler for AstraZeneca's Symbicort aerosol inhaler, and also the launch of Adherium's next generation device for AstraZeneca's Symbicort Turbuhaler.

About Adherium

Adherium is a provider of digital health solutions. The Company develops, manufactures and supplies patients, pharmaceutical companies, healthcare providers and contract research organizations with the broadest range of "smart" medication sensors for respiratory medications to address sub-optimal medication use and improve health outcomes in chronic disease.

Adherium operates globally from bases in the USA, Europe and Australasia.

Inquiries

Company: Arik Anderson, CEO, ArikA@adherium.com, contact@adherium.com, www.adherium.com

Media: *Europe:* Sue Charles/Tim Watson, Instinctif Partners, +44 20 7457 2020, adherium@instinctif.com

United States: Dawn Fallon, Lazar Partners, +1 646-871-8481, dfallon@lazarpartners.com

Australia: Rudi Michaelson, Monsoon Communications, +61 3 9620 3333, rudim@monsoon.com.au